StocksMedium•4 November 2026•
1 min read
NewAmsterdam Pharma Reports Narrower-Than-Expected Q3 2026 Loss
Key Facts
1NewAmsterdam Pharma reported a quarterly loss of $0.14 per share, significantly narrower than the Zacks Consensus Estimate of a $0.5 loss.
NewAmsterdam Pharma reported a quarterly loss of $0.14 per share for the third quarter of 2026. According to Zacks, the result was significantly narrower than the consensus estimate of a $0.5 loss per share, with the company also beating revenue expectations for the period.
The financial results demonstrated stronger resilience than market participants had projected for NewAmsterdam Pharma. Shares of NAMS closed at $19.9 on November 3, 2026, having traded between a low of $19.59 and a high of $20.46 during that session.